GET DAILY SIGNALSSensus Healthcare (SRTS): Navigating the Path to the $5.00 Analyst Target
Key Takeaways
- The $5.00 central target is the arithmetic mean of the three most recent, clearly attributed analyst price targets (about $5.17), rounded to a clean level; the individual targets range from $4.00 to $6.00.
- Sensus Healthcare, Inc. (SRTS) last traded near $2.75, so reaching $5.00 would require an advance of roughly 80%, a very large move by any standard.
- Coverage is thin—three firms—and all rate the stock a Buy, but the target has been cut repeatedly over the past year as results disappointed.
- The strongest supporting factors are new 2026 CPT reimbursement codes and an expected third-quarter recovery from delayed system sales.
- The biggest risks are steep revenue declines, persistent losses, financing-related delays, and customer concentration.
- For more detail on SRTS's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Analyst Price Targets and Consensus View
Sensus Healthcare is a medical device maker best known for its superficial radiation therapy (SRT) systems—the SRT-100/Vision—used to treat non-melanoma skin cancers and keloids. The $5.00 figure used here is not an official consensus but a calculated average of three current, verifiable analyst price targets: Alliance Global Partners at $5.50 (maintained August 17, 2026), Maxim Group at $6.00 (maintained August 15, 2026), and Lake Street at $4.00 (lowered from $4.50 on August 14, 2026). Their arithmetic mean is about $5.17, rounded to $5.00, with a range of $4.00 to $6.00.
All three firms rate the stock a Buy, but the wide $4.00-to-$6.00 spread signals real disagreement about how quickly a recovery takes hold. Maxim's Anthony Vendetti is the most optimistic, arguing the company is nearing an operational inflection point on strengthening demand and new reimbursement codes. Lake Street's Ben Haynor took a more cautious view after the second quarter, cutting his target. Notably, the average target has fallen sharply—from around $8.00 a year ago to roughly $5.17 today—reflecting repeated downward revisions rather than a stable, rising trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock near $2.75 and a 52-week range of roughly $2.66 to $5.49, the $5.00 target implies about an 80% upside, a very large move that would effectively return the shares to their prior peak zone. The path would require a decisive turnaround in revenue recognition. In the second quarter of 2026, revenue fell to about $2.3 million from $7.3 million a year earlier, largely because eight SRT systems—each roughly $250,000—were delayed by third-party financing issues. Management has since severed ties with the bank involved and expects those sales to be recognized in the third quarter, a key near-term catalyst that analysts believe could re-accelerate the top line.
What Could Support a Move Toward the Target
The most compelling support is reimbursement. New dedicated CPT (Current Procedural Terminology) codes took effect in 2026, and early CMS (Centers for Medicare & Medicaid Services) reimbursement under those codes could improve physician economics and drive broader adoption of the SRT platform. Maxim also points to emerging international opportunities in markets such as Australia and New Zealand. If the delayed systems are recognized as guided and demand from new customers materializes, revenue growth forecasts—estimated at a roughly 20% annual pace by some aggregators—could begin to close the gap between the current price and analyst targets.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company swung to a wider GAAP (generally accepted accounting principles) net loss in the second quarter, including a valuation allowance, and remains unprofitable on a trailing basis. Sales are heavily dependent on a limited number of large customers—the absence of its largest customer's orders has previously driven dramatic shortfalls—and financing delays have repeatedly pushed revenue recognition out. Thin analyst coverage also means the "consensus" rests on just three voices, and the steady downward revision of targets over the past year shows that prior recovery assumptions have not been met.
Technical Levels and Market Structure
The shares sit near the bottom of their 52-week range, with the prior high around $5.49 acting as the nearest major resistance zone—coincidentally just above the $5.00 target. The $2.66 area represents a key support level. In September 2026, the stock slipped below its 50-day moving average, reflecting waning short-term momentum, and any sustained advance would first need to reclaim intermediate moving averages before approaching the $5.00 level. From what I see, monitoring these levels closely remains essential.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though no firm horizon is explicitly stated in these reports. Investors should watch the third-quarter earnings release for evidence that the eight delayed systems were recognized, any updates on adoption of the new 2026 CPT codes and CMS reimbursement, gross-margin and cash trends, and whether analysts raise or cut their targets after results. Additional coverage initiations or downgrades would also matter given how thin the current consensus is.
Using Tickeron’s AI Daily Buy/Sell Signals for Additional Insight
Beyond the fundamentals, I find it helpful to layer in automated signals when evaluating momentum for names like SRTS. Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. This approach can surface opportunities or confirm trends more efficiently than manual review alone, and I often cross-reference it with analyst targets to build a fuller picture.
Final Assessment
Can Sensus Healthcare reach $5.00? The target—an average of three current analyst targets ranging from $4.00 to $6.00—is mathematically plausible but demanding, requiring roughly an 80% advance from near $2.75. The bull case rests on new reimbursement codes and a third-quarter revenue recovery from delayed system sales, while the bear case points to steep losses, financing disruption, and customer concentration. Analysts agree the stock is a Buy but disagree sharply on magnitude, and their targets have been falling, not rising. The next earnings report and any revision to those targets will be the clearest test of whether the $5.00 objective remains realistic.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SRTS's RSI Oscillator recovers from oversold territory
The RSI Indicator for SRTS moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 226 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTS as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for SRTS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 27 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.228) is normal, around the industry mean (4.204). P/E Ratio (-2.926) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement